Selegiline transdermal - Somerset Pharmaceuticals

Drug Profile

Selegiline transdermal - Somerset Pharmaceuticals

Alternative Names: Emsam

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Somerset Pharmaceuticals
  • Class Analgesics; Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Major depressive disorder
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 29 May 2009 Selegiline is no longer licensed to Bristol-Myers Squibb in USA; Dey LP aquires marketing rights
  • 28 Jul 2008 Somerset Pharmaceuticals has become a wholly owned subsidiary of Mylan Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top